{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:29:54Z","timestamp":1773286194846,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ejim.2013.01.009","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T10:00:37Z","timestamp":1359626437000},"page":"207-212","source":"Crossref","is-referenced-by-count":33,"title":["Incretin-based therapies in the treatment of type 2 diabetes \u2014 More than meets the eye?"],"prefix":"10.1016","volume":"24","author":[{"given":"Krzysztof","family":"\u0141abuzek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Koz\u0142owski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawid","family":"Szkud\u0142apski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Koz\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2013.01.009_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejim.2013.01.009_bb0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/diab.37.2.200","article-title":"Incretin effect due to increased secretion and decreased clearance of insulin in normal humans","volume":"37","author":"Shuster","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0020","first-page":"E349","article-title":"Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans","volume":"254","author":"Tillil","year":"1988","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0025","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2337\/diab.36.12.1365","article-title":"Insulin secretion and clearance: comparison after oral and intravenous glucose","volume":"36","author":"Shapiro","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1463-1326.2007.00765.x","article-title":"Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"9","author":"Deacon","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2013.01.009_bb0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and non-diabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptors","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/me.2002-0306","article-title":"Glucagon-like peptides: regulators of cell proliferation, differentation and apoptosis","volume":"17","author":"Drucker","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0050","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cmet.2005.12.008","article-title":"cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in \u03b2 cells","volume":"3","author":"Knoch","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejim.2013.01.009_bb0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0065","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7\u201336) amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.01.009_bb0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0075","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","article-title":"Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia","volume":"46","author":"Meier","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0085","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/dmrr.1202","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review","volume":"27","author":"Aroda","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ejim.2013.01.009_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.01.009_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1620\/tjem.223.133","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes","volume":"223","author":"Ogawa","year":"2010","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.ejim.2013.01.009_bb0100","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/HJH.0b013e328341939d","article-title":"Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats","volume":"29","author":"Pacheco","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2013.01.009_bb0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2013.01.009_bb0110","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2013.01.009_bb0115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(10)62299-4","article-title":"Cardiovascular safety and diabetes drug development","volume":"377","author":"Drucker","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2013.01.009_bb0120","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0125","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0130","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2013.01.009_bb0135","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1 based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0150","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras G12D mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0155","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0165","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0170","first-page":"1285","article-title":"Ductal metaplasia of human exocrine pancreas and its association with carcinoma","volume":"45","author":"Parsa","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejim.2013.01.009_bb0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0002-9610(82)90518-9","article-title":"Origin of tubular complexes in human acute pancreatitis","volume":"144","author":"Bockman","year":"1982","journal-title":"Am J Surg"},{"key":"10.1016\/j.ejim.2013.01.009_bb0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1101\/gad.184701","article-title":"A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease","volume":"15","author":"Wagner","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejim.2013.01.009_bb0185","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2010.02382.x","article-title":"Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis","volume":"64","author":"Engel","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2013.01.009_bb0190","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1053\/j.gastro.2009.12.005","article-title":"Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia","volume":"138","author":"Strobel","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0195","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","article-title":"Exenatide (Exendin-4) \u2014 induced pancreatitis: a case report","volume":"26","author":"Denker","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.01.009_bb0210","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0215","doi-asserted-by":"crossref","first-page":"559","DOI":"10.18553\/jmcp.2005.11.7.559","article-title":"Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes","volume":"11","author":"Shetty","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ejim.2013.01.009_bb0220","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Anti-diabetic therapies affect risk of pancreatic cancer","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","article-title":"Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials","volume":"27","author":"Monami","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2013.01.009_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2013.01.009_bb0235","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0245","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diabres.2010.02.017","article-title":"Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?","volume":"88","author":"Stulc","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejim.2013.01.009_bb0255","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like-peptide 1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0260","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.regpep.2006.07.003","article-title":"DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells","volume":"137","author":"Masur","year":"2006","journal-title":"Regul Pept"},{"key":"10.1016\/j.ejim.2013.01.009_bb0265","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1073\/pnas.96.4.1569","article-title":"Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2","volume":"96","author":"Munroe","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2013.01.009_bb0270","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2741\/2787","article-title":"The role of CD26\/dipeptidil peptidase IV in cancer","volume":"13","author":"Havre","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.ejim.2013.01.009_bb0275","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1357-2725(03)00262-0","article-title":"Dipeptidyl peptidase IV activity and\/or structure homologues (DASH) and their substrates in cancer","volume":"36","author":"Busek","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0280","first-page":"2753","article-title":"Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma","volume":"62","author":"Kajiyama","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejim.2013.01.009_bb0285","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1010930918055","article-title":"Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells","volume":"18","author":"Pethiyagoda","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ejim.2013.01.009_bb0290","first-page":"2278","article-title":"Dipeptidyl peptidase overexpression induces upregulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells","volume":"63","author":"Kajiyama","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejim.2013.01.009_bb0295","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1067\/mob.2003.169","article-title":"Dipeptidyl peptidase IV expression in endometrial endometroid adenocarcinoma and its inverse correlation with tumor grade","volume":"188","author":"Khin","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0300","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.177.4.1135","article-title":"A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase","volume":"177","author":"Morrison","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejim.2013.01.009_bb0305","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/0008-5472.CAN-04-1852","article-title":"Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway","volume":"65","author":"Wesley","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejim.2013.01.009_bb0310","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0022-5347(05)68354-1","article-title":"Activation of extracellular signal-regulated kinase in human prostate cancer","volume":"162","author":"Price","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0315","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ijc.20091","article-title":"Role of dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells","volume":"109","author":"Wesley","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejim.2013.01.009_bb0320","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0046-8177(94)90098-1","article-title":"CD26\/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and subset of T-cell non-Hodkin's lymphomas","volume":"25","author":"Carbone","year":"1994","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0325","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1054\/bjoc.2000.1410","article-title":"Preoperative serum CD26 levels: diagnostic efficency and predictive value for colorectal cancer","volume":"83","author":"Cordero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejim.2013.01.009_bb0330","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11695-008-9599-3","article-title":"Obesity, pancreatitis and pancreatic cancer","volume":"18","author":"Gumbs","year":"2008","journal-title":"Obes Surg"},{"key":"10.1016\/j.ejim.2013.01.009_bb0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-009-1556-8","article-title":"Pancreatic duct replication is increased with obesity and type 2 diabetes in humans","volume":"53","author":"Butler","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2013.01.009_bb0340","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","article-title":"Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats","volume":"141","author":"Perfetti","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0345","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/371606a0","article-title":"Insulin-promoter-factor-1 is required for pancreas development in mice","volume":"371","author":"Jonsson","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2013.01.009_bb0350","first-page":"12","article-title":"A newly discovered role of transcription factors involved in pancreatic development and the pathogenesis of type 2 diabetes mellitus","volume":"110","author":"Habener","year":"1998","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1016\/j.ejim.2013.01.009_bb0355","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2013.01.009_bb0360","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/en.2004-0015","article-title":"Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system","volume":"145","author":"Brubaker","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.01.009_bb0365","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/150960","article-title":"Clinical Relevance of KRAS in Human Cancers","volume":"2010","author":"Jan\u010d\u00edk","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.ejim.2013.01.009_bb0375","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.01.009_bb0380","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2013.01.009_bb0385","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.01.009_bb0390","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.01.009_bb0395","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2013.01.009_bb0400","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.01.009_bb0405","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2013.01.009_bb0410","first-page":"CD006739","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2013.01.009_bb0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","article-title":"Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes","volume":"10","author":"Williams-Herman","year":"2010","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.ejim.2013.01.009_bb0420","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1463-1326.2010.01214.x","article-title":"An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and II clinical trials","volume":"12","author":"Ligueros-Saylan","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2013.01.009_bb0425","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV, (CD26): role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"key":"10.1016\/j.ejim.2013.01.009_bb9000","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T02:13:14Z","timestamp":1644199994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620513000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0953620513000149"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2013.01.009","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}